North America Mycoplasma Testing Market

North America Mycoplasma Testing Market Size & Growth (2022 to 2027):

According to the report, the Size of the North America Mycoplasma Testing Market is valued at USD 210.74 Million in 2022 and is projected to be growing at a CAGR of 11.5%, to reach USD 363.17 Million by 2027 during the forecast period 2022 to 2027.

DRIVERS

Factors such as high R&D expenditure by bio-pharmaceutical companies, increase in government initiatives and research, high degree technological advancements, along with demand for rapid, accurate & affordable tests and increase in contamination of cell cultures further stimulate the mycoplasma market.

The other factor includes the efficiency of polymerase chain reaction tests that is increasing application in clinical diagnostics, the increasing demand for personalized and precision medicine, and technological advancements and applications in drug development.

Mycoplasma infection is complex to see under a microscope and requires specific tests to be detected. Infection can have an acute impact on experimental work depending on the species present. Mycoplasma organisms can affect cell growth, teratogenic, metabolism, and response to chemotherapy. Increased research activity by pharmaceutical and biotechnology companies, increased government support and funding for research activities, and growing contamination of cell cultures around the world are the few factors responsible for the high CAGR market for the upcoming forecast period.

RESTRAINTS

However, there are some strict government regulations in several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major obstacles to the growth of the mycoplasma testing market.

Factors such as the lack of trained professionals, physicians and the lack of standards and protocols are limiting the growth of the market. For optimum effectiveness, the mycoplasma testing procedure should be performed by trained professionals with sufficient knowledge of the nuances of this area. Handling the instruments used in mycoplasma testing also requires experience and professionals. Hence, the lack of a sufficiently skilled workforce is hampering the growth of the Mycoplasma Testing market.

OPPORTUNITIES

Developments in techniques such as Polymerase Chain Reaction (PCR), Enzyme Immunoassay (ELISA), Enzyme Reaction and DNA Staining during pandemic, has increased the growth rate. The polymerase chain reaction (PCR) very popular and is expected have the highest CAGR for the forecast period. Factors that can be attributed to the popularity of PCR are due to the precision, speed and flexibility that this technique offers in life science research.

CHALLENGES

Mycoplasma organisms can affect various cellular response and can give false results as they are techniques sensitive. Hence care should be taken to check for the presence of Mycoplasma in cell banks and biotechnology labs, otherwise it can further spoil cell culture based research, which is challenging the growth rate of the market.

This research report on the North America Mycoplasma Testing Market has been segmented and sub-segmented into the following categories

By Product:

• Kits & Reagents
• Instruments
• Services

By Technique:

• PCR
• ELSA
• Direct Assays
• Indirect Assays
• Microbial Culture Techniques
• Enzymatic Methods
• DNA Staining

By Application:

• Cell Line Testing
• Virus Testing
• End-Of-Production Cell Testing
• Others

By End-User:

• Pharmaceutical Companies
• Contract Research Organizations
• Academic Research Institutes
• Cell Banks

By Country:

• US
• Canada
• Rest of North America.

REGIONAL ANALYSIS

The North America Mycoplasma Testing market is expected to exhibit a healthy CAGR during the forecast period. The U.S mycoplasma testing market and is expected to maintain the same position for a few more years. This region is expected to increase its market share in the future, due to its well-established healthcare industry and the increasing prevalence of chronic diseases in the region. Other growth factors in this region are the presence of global biotechnology companies and pharmaceutical players and increased investment in R&D activities in the region.

Canada Mycoplasma Testing Market is also expected to have a healthy growth rate, this is due to the increase in healthcare costs associated with the rapid uptake of point-of-care testing, expanding healthcare spending and increased investment by the government.

Promising Companies leading the North America Mycoplasma Testing Market Profiled in the Report are PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, WuXi AppTec.,